Overview Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects Status: Not yet recruiting Trial end date: 2024-10-07 Target enrollment: Participant gender: Summary This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine. Phase: Phase 3 Details Lead Sponsor: Biohaven Pharmaceuticals, Inc.